Israeli regenerative medicine company CollPlant Holdings Ltd. (TASE: CLPT) has filed a prospectus with the US Securities and Exchange Commission (SEC) to raise up to $25 million on Wall Street.
CollPlant develops tissue repair products based on collagen from plants. The Ness Ziona based company has produced the first plant-derived source of Type I recombinant human collagen. Last week, the company announced that it had been awarded the EU CE Mark for its VergenixSTR, a soft tissue repair matrix for the treatment of tendinopathy.
In the filing to the SEC, the company said it plans listing on Nasdaq under the “CLGN” ticker and said Ladenburg Thalmann & Co. is the sole bookrunner for the offering. No pricing terms were disclosed. CollPlant has been trading on the Tel Aviv Stock Exchange since 2010, following a reverse merger.
“We believe the market opportunity for our current product candidates utilizing our rhCollagen platform technology exceeds $5 billion,” the company said.
CollPlant is led by CEO Yehiel Tal.
Published by Globes [online], Israel business news - www.globes-online.com - on October 25, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016